The research about overexpression gene identification with neuroblastoma on Biochip

神经母细胞瘤过表达基因生物芯片鉴定研究

• 批准号: 14571705
• 负责人: KONDO Satoshi
• 金额: $ 1.86万
• 依托单位: Nagoya City University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2002
• 资助国家: 日本
• 起止时间: 2002 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14571705/
• 关键词: neuroblastoma; cDNA microarray; spontaneous differentiation and regression; BioChip(microarray); 病理組織; 正常交感神経節

This research planned to fine overexpression gene of neuroblastoma by using Biochip at first. However, technically, because it was impossible, it decided to identify the gene which participates in the mechanism of spontaneous differentiation and regression with cDNA microarray.Neuroblastoma (NB), one of the most common solid tumors among children, is known found under the age of one year often show spontaneous differentiation and regression. But some shift to unfavorable type and progress to an advance stage with metastasis. Therefore, it is very important to know which tumor will regress or progress. Using histological classified by the degree of maturation, we analyzed gene-expression profiles of 14 NB tumors on coda microarray to elucidate the mechanisms of spontaneous differentiation and regression. Computational analysis identified the gene which has a difference between differentiating NB tumors and poorly differentiated NB tumors. Differentiating NB group included genes associated with cell maturation and apoptosis. Poorly differentiated NB group included in relation to tumorigenesis. The future, examination will be added ; it thinks that we want to be able to lead to development of new therapeutic strategies.

本研究首先拟利用生物芯片技术对神经母细胞瘤的过表达基因进行精细化研究。神经母细胞瘤（Neuroblastoma，NB）是儿童最常见的实体瘤之一，在一岁以下儿童中发现的肿瘤常表现为自发性分化和退化，但由于技术上不可能，因此决定用cDNA微阵列鉴定参与自发性分化和退化机制的基因。但也有部分转为不利型，并随着转移而进展到晚期.因此，了解哪种肿瘤会消退或进展非常重要。使用成熟程度的组织学分类，我们分析了14个NB肿瘤的基因表达谱的尾芯片，以阐明自发分化和退化的机制。计算分析鉴定了在分化NB肿瘤和低分化NB肿瘤之间具有差异的基因。分化NB组包括与细胞成熟和凋亡相关的基因。低分化NB组与肿瘤发生有关。未来，将增加检查;它认为我们希望能够导致新的治疗策略的发展。